Polyzoidis Stavros, Ashkan Keyoumars
Department of Neurosurgery, King's College Hospital, Denmark Hill London, SE5 9RS, UK.
Expert Rev Anticancer Ther. 2014 Jul;14(7):761-3. doi: 10.1586/14737140.2014.921571. Epub 2014 May 21.
Dendritic cell immunotherapy is emerging as a promising addition to the multimodal treatment of patients with glioblastoma multiform. Initial Phase I and II trials have demonstrated favorable outcomes with minimal toxicity. In this editorial, the current status and the future challenges of this therapy are discussed.
树突状细胞免疫疗法正在成为多形性胶质母细胞瘤患者多模式治疗中一种有前景的补充疗法。最初的I期和II期试验已证明该疗法疗效良好且毒性极小。在这篇社论中，讨论了这种疗法的现状和未来挑战。
